Treatment of Hypertension
Information source: National Heart, Lung, and Blood Institute (NHLBI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
Intervention: chlorothiazide (Drug); Rauwolfia alkaloids (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI) Official(s) and/or principal investigator(s):
Anthony Damato, Affiliation: USPHS Hospital
Richard Thurm, Affiliation: USPHS Hospital
Christfried Urner, Affiliation: USPHS Hospital
John Vaillancourt, Affiliation: USPHS Hospital
J. Warbasse, Affiliation: USPHS Hospital
Robert Wells, Affiliation: USPHS Hospital
Summary
To determine whether the long-term treatment of essential hypertension without significant
target organ disease materially influenced mortality and/or cardiovascular renal morbidity.
Clinical Details
Study design: Prevention, Randomized, Double-Blind, Placebo Control
Detailed description:
BACKGROUND:
This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and
followed a cooperative study of the treatment of renal hypertension initiated in 1960 to
evaluate the relative efficacy of several recognized drug regimens for reduction of blood
pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the
trial.
DESIGN NARRATIVE:
Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients were
assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to
placebo.
Eligibility
Minimum age: 21 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm
Hg.
Locations and Contacts
Additional Information
Related publications: [No authors listed] Morbidity and mortality in mild essential hypertension. Circ Res. 1972 Sep;31(9):Suppl 2:110-24. No abstract available. U.S. Public Health Service Hospitals Cooperative Study Group. Smith WM, et al: Intervention Trial in Mild Hypertension. Epidemiology and Control of Hypertension. Paul, O (Ed.), Symposia Specialists, Miami, l975, pp. 46l-483. Elharrar V, Foster PR, Jirak TL, Gaum WE, Zipes DP. Alterations in canine myocardial excitability during ischemia. Circ Res. 1977 Jan;40(1):98-105. Smith WM. Mild essential hypertension: benefit of treatment: discussion. Ann N Y Acad Sci. 1978 Mar 30;304:74-80. No abstract available. Smith WM, Edlavitch SA, and Krushat WM: U.S. Public Health Service Hospitals Intervention Trial in Mild Hypertension. Hypertension, Determinants, Complications, and Intervention. Onesti G, and Klimt C, (Eds.), Grune & Stratton, New York, l979, pp. 38l-399. Smith WM: Hypertension--Effectiveness of Early Treatment in Preventing Sequellae. Proceedings of the Eisenhower Medical Center. Preventive Interventions in the Practice of Medicine, Spring, l979, pp. 8l-87. Smith WM, Edlavitch SA, and Krushat WM: Prevention of Stroke in Mild Hypertension: Public Health Service Hospitals Trial. Perspectives in Cardiovascular Research, Vol. 4. Prophylactic Approach to Hypertensive Diseases, Yamori Y, Lovenberg W, and Freis ED, (Eds.), Raven Press, New York, l979, pp. 53-62.
Starting date: April 1966
Last updated: June 23, 2005
|
